Clinical Trials Browser

Phase 1/2 × Interventional × Cytokine Release Syndrome × Clear all

NCT03016377 2025-10-27

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06703216 2025-06-15

PACER

Phase 1/2 Not yet recruiting

Cytokine Release Syndrome, Burkitt Lymphoma

NCT04082910 2022-04-13

Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells

Phase 1/2 Unknown

Other hematologic neoplasm

Cytokine Release Syndrome, Hematologic Neoplasms

NCT02000817 2019-06-24

Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients

Phase 1/2 Completed

30 enrolled 21 charts

Cytokine Release Syndrome, Diabetes Mellitus, Diabetes Mellitus, Type 1, Epstein-Barr Virus Infections